S'abonner

The association between phylogenetic lineage and the subclinical phenotype of pulmonary tuberculosis: A retrospective 2-cohort study - 03/02/24

Doi : 10.1016/j.jinf.2023.12.006 
Richard Long a, , Matthew Croxen b, c, d, e, Robyn Lee f, Alexander Doroshenko a, Angela Lau a, Leyla Asadi a, Courtney Heffernan a, Catherine Paulsen a, Mary Lou Egedahl a, Colin Lloyd c, g, Vincent Li c, Gregory Tyrrell b, c, d
a Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada 
b Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada 
c Alberta Precision Laboratories, Edmonton, Alberta, Canada 
d Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada 
e Women and Children’s Health Research Institute, University of Alberta, Edmonton, Alberta, Canada 
f Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada 
g Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Manitoba, Canada 

Correspondence to: Room 8325, Aberhart Centre, 11402 University Avenue, Edmonton, Alberta T6G 2J3, Canada.Room 8325, Aberhart Centre, 11402 University AvenueEdmontonAlbertaT6G 2J3Canada

Summary

Background

Subclinical pulmonary tuberculosis (PTB) is an asymptomatic disease state between established TB infection and symptomatic (clinical) TB disease. It is present in 20-25% of PTB patients in high-income countries. Mycobacterium tuberculosis complex (MTBC) genetic heterogeneity, and differential host immunological responses, have been implicated in its pathogenesis.

Methods

To determine the association between MTBC lineage and PTB disease phenotype, we used two retrospective cohorts of PTB patients in Canada and two independent lineage attribution methods (DNA fingerprinting and genome sequencing). The first cohort, Cohort 1, consisted of consecutively diagnosed PTB patients between 2014 and 2020. The second, Cohort 2, consisted of newly-arrived foreign-born PTB patients who either were or were not referred for post-landing medical surveillance between 2004 and 2017. Univariable and multivariable logistic regression models were sequentially fitted to both cohorts, adjusting for age, sex, disease type, drug resistance and HIV. Evolution of radiographic features was correlated to lineage in Cohort 2.

Findings

Cohort 1 and 2 included 874 (209 subclinical) and 111 (44 subclinical) patients, respectively. In both cohorts, subclinical patients were more likely than clinical patients to have relapse/retreatment disease, be smear-negative, have longer times-to-culture positivity and to harbor an ancestral MTBC lineage (Indo-Oceanic or Mycobacterium africanum). Relapse/retreatment disease and ancestral MTBC lineage were independent predictors of subclinical disease (ORs and 95% CIs in Cohort 1, 1.85 [1.07,3.28], p < 0.029 and 2.30 [1.66,3.18], p < 0.001, respectively, and Cohort 2, 5.74 [1.37–24.06], p < 0.017 and 3.21 (1.29,7.97], p < 0.012, respectively). The geographic distribution of Indo-Oceanic strains causing subclinical disease was uneven. Non-progressive lung disease was more common in patients infected with ancestral than modern lineages in Cohort 2, 56.0% vs 25.4%, p < 0.005.

Interpretation

MTBC lineage is a strong predictor of PTB disease phenotype. The genetic drivers of this association, and the relative contribution of other explanatory variables, are unknown.

Le texte complet de cet article est disponible en PDF.

Highlights

Past TB disease and ancestral TB lineage are independent predictors of subclinical pulmonary TB disease.
Progressive lung disease is more common in TB patients infected with a modern lineage.
Connecting subclinical TB to ancestral lineage supports co-evolution of TB and humans.

Le texte complet de cet article est disponible en PDF.

Keywords : Pulmonary tuberculosis


Plan


© 2024  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 88 - N° 2

P. 123-131 - février 2024 Retour au numéro
Article précédent Article précédent
  • Economic burden attributable to healthcare-associated infections at western China hospitals: 6 Year, prospective cohort study
  • Yu Lv, Xiaobo Huang, Jiayu Wu, Xueqin Xiao, Chunhua Ma, Xiaoyun Jiang, Ping Zhou, Linlin Liu, Yiguo Jiang, Anna Zou, Hui Niu, Juhua Sun, Li Hou, Xiaomeng Wang, Yulin Dai, Shuling Peng, Xiaorong Deng, Hong Xia, Yao Guo, Defen Wang, Ting Huang, Chunyu Li, Lirong He, Fengqing Xiong, Hongmei Xiong, Hongmei Cao, Jie Lu, Xingfeng Liu, Xiaohong Jian, Wanzhen Luo, Yanmei An, Yumei Wu, Keqin Deng, Xiaoli Kang, Xiaorong Chen, Beibei Tang, Li Li, Qian Xiang
| Article suivant Article suivant
  • Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease: Data from the French Tw-IRD registry
  • Damien Caillet Portillo, Xavier Puéchal, Maëva Masson, Marie Kostine, Alexia Michaut, André Ramon, Daniel Wendling, Nathalie Costedoat-Chalumeau, Pascal Richette, Hubert Marotte, Justine Vix-Portet, Jean-Jacques Dubost, Sébastien Ottaviani, Gaël Mouterde, Anne Grasland, Aline Frazier, Vincent Germain, Fabienne Coury, Anne Tournadre, Martin Soubrier, Laurent Cavalie, Pauline Brevet, Laurent Zabraniecki, Bénédicte Jamard, Guillaume Couture, Laurent Arnaud, Christophe Richez, Yannick Degboé, Adeline Ruyssen-witrand, Arnaud Constantin

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.